Maxigen Biotech Inc (1783) — Cash Flow Quality Index
Maxigen Biotech Inc (1783) has a Cash Flow Quality Index of 1.51x as of March 2026. Operating cash flow of NT$79.84 Million exceeds net income of NT$52.79 Million, indicating high earnings quality where cash backs reported profits. Explore how efficiently does Maxigen Biotech Inc generate cash to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Maxigen Biotech Inc Cash Flow Quality Index (2009–2025)
Historical Cash Flow Quality Index for Maxigen Biotech Inc across 12 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 1783 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Maxigen Biotech Inc (2009–2025)
Year-by-year earnings quality comparison for Maxigen Biotech Inc. For live market cap and the full company financial profile, see Maxigen Biotech Inc (1783) total market value.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.95x | NT$290.22 Million | NT$304.89 Million | ▼ -28.0% |
| 2024 | 1.32x | NT$298.22 Million | NT$225.54 Million | ▲ +49.2% |
| 2023 | 0.89x | NT$171.20 Million | NT$193.14 Million | ▼ -45.2% |
| 2022 | 1.62x | NT$268.34 Million | NT$165.78 Million | ▲ +34.2% |
| 2021 | 1.21x | NT$117.59 Million | NT$97.47 Million | ▲ +24.4% |
| 2020 | 0.97x | NT$74.39 Million | NT$76.74 Million | ▼ -25.3% |
| 2019 | 1.30x | NT$94.42 Million | NT$72.80 Million | ▼ -56.4% |
| 2018 | 2.98x | NT$170.58 Million | NT$57.31 Million | ▲ +20.7% |
| 2017 | 2.47x | NT$41.18 Million | NT$16.70 Million | ▲ +137.7% |
| 2013 | -6.54x | NT$-22.34 Million | NT$3.42 Million | ▼ -203.2% |
| 2012 | 6.34x | NT$17.53 Million | NT$2.76 Million | ▲ +315.5% |
| 2009 | 1.53x | NT$19.27 Million | NT$12.63 Million | — |